Hajhashemi, V; Ghannadi, A; Sharif, B (2003). „Anti-inflammatory and analgesic properties of the leaf extracts and essential oil of Lavandula angustifolia Mill”. Journal of Ethnopharmacology. 89 (1): 67—71. PMID14522434. doi:10.1016/S0378-8741(03)00234-4.
Kasper, S; Gastpar, M; Müller, WE; Volz, HP; Möller, HJ; Dienel, A; Schläfke, S (2010). „Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial”. International Clinical Psychopharmacology. 25 (5): 277—87. PMID20512042. doi:10.1097/YIC.0b013e32833b3242.
Perry, R; Terry, R; Watson, L. K.; Ernst, E (2012). „Is lavender an anxiolytic drug? A systematic review of randomised clinical trials”. Phytomedicine. 19 (8–9): 825—35. PMID22464012. doi:10.1016/j.phymed.2012.02.013.
Henley DV, Lipson N, Korach KS, Bloch CA (2007). „Prepubertal gynecomastia linked to lavender and tea tree oils”. New England Journal of Medicine. 356 (5): 479—485. PMID17267908. doi:10.1056/NEJMoa064725.
Diaz A, Luque L, Badar Z, Kornic S, Danon M (2016). „Prepubertal gynecomastia and chronic lavender exposure: report of three cases”. J. Pediatr. Endocrinol. Metab. 29 (1): 103—107. PMID26353172. doi:10.1515/jpem-2015-0248.
Placzek, M; Frömel, W; Eberlein, B; Gilbertz, KP; Przybilla, B (2007). „Evaluation of phototoxic properties of fragrances.”. Acta Dermato-venereologica. 87 (4): 312—6. PMID17598033. doi:10.2340/00015555-0251.
Hajhashemi, V; Ghannadi, A; Sharif, B (2003). „Anti-inflammatory and analgesic properties of the leaf extracts and essential oil of Lavandula angustifolia Mill”. Journal of Ethnopharmacology. 89 (1): 67—71. PMID14522434. doi:10.1016/S0378-8741(03)00234-4.
Kasper, S; Gastpar, M; Müller, WE; Volz, HP; Möller, HJ; Dienel, A; Schläfke, S (2010). „Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial”. International Clinical Psychopharmacology. 25 (5): 277—87. PMID20512042. doi:10.1097/YIC.0b013e32833b3242.
Perry, R; Terry, R; Watson, L. K.; Ernst, E (2012). „Is lavender an anxiolytic drug? A systematic review of randomised clinical trials”. Phytomedicine. 19 (8–9): 825—35. PMID22464012. doi:10.1016/j.phymed.2012.02.013.
Henley DV, Lipson N, Korach KS, Bloch CA (2007). „Prepubertal gynecomastia linked to lavender and tea tree oils”. New England Journal of Medicine. 356 (5): 479—485. PMID17267908. doi:10.1056/NEJMoa064725.
Diaz A, Luque L, Badar Z, Kornic S, Danon M (2016). „Prepubertal gynecomastia and chronic lavender exposure: report of three cases”. J. Pediatr. Endocrinol. Metab. 29 (1): 103—107. PMID26353172. doi:10.1515/jpem-2015-0248.
Placzek, M; Frömel, W; Eberlein, B; Gilbertz, KP; Przybilla, B (2007). „Evaluation of phototoxic properties of fragrances.”. Acta Dermato-venereologica. 87 (4): 312—6. PMID17598033. doi:10.2340/00015555-0251.
nccih.nih.gov
„Lavender: Science and Safety”. National Center for Complementary and Integrative Health. mart 2007. Приступљено 5. 11. 2013.